{
  "schemaVersion": 1,
  "id": "research-292",
  "slug": "292-what-a-withdrawn-compounding-nomination-means",
  "title": "What a withdrawn compounding nomination means",
  "catalogLabel": "PEG-MGF",
  "productCollection": "https://heritagebiolabs.com/research-library/products/peg-mgf",
  "productHandles": [
    "peg-mgf-446"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/peg-mgf-446"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 282,
  "sourceYears": [
    2026
  ],
  "paragraphs": [
    "Short chains of amino acids connected by peptide bonds are peptides. Some interact with receptors, and a chemical modification can change how a peptide behaves. PEG-MGF refers to a synthetic MGF-related peptide joined to polyethylene glycol, or PEG. The FDA has tracked it separately from unmodified mechano growth factor. Its 2026 records illustrate the difference between a nomination to a compounding list and evidence supporting an approved drug. [1, 2]",
    "A compounding nomination asks the agency to consider a bulk substance for a specific regulatory list. FDA’s record says the nominator withdrew the PEG-MGF nomination. The agency therefore removed the substance from Category 2 of its interim policy list. That category had identified nominated substances that might present significant safety risks. The record gives the procedural reason for the change, which is the withdrawal itself. It separately records FDA’s intention to seek advice about potential inclusion on the section 503A list. [1, 2]",
    "FDA announced that it planned to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. An advisory meeting allows the committee to consider evidence and advise the agency. The announcement describes a planned discussion of a bulk ingredient, with a scope defined by the compounding question. FDA’s safety page continued to describe the human evidence gap for PEG-MGF after the nomination was withdrawn. [1, 2, 3]",
    "This sequence shows why the date and reason next to a status change matter. The withdrawal documents what happened to one nomination. The committee notice documents a planned review. The safety record explains the evidence the agency had identified. Reading these records together preserves the distinctions between administrative history, the evidence base and a drug approval decision. [1, 2, 3]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA (record updated 2026-04-22).",
      "url": "https://www.fda.gov/media/94155/download?attachment="
    },
    {
      "number": 2,
      "citation": "U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee. FDA (record updated 2026-04-15).",
      "url": "https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"
    },
    {
      "number": 3,
      "citation": "U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA (record updated 2026-04-22).",
      "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/292-what-a-withdrawn-compounding-nomination-means",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/292-what-a-withdrawn-compounding-nomination-means.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/292-what-a-withdrawn-compounding-nomination-means.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 059 - PEG-MGF.docx",
    "sourceArticleNumber": 292,
    "contentSha256": "ae168db85680084d15801f0654ee04eee21c8145f0411010c848d9dbd8716b0b",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
